Business
Faron announces R&D Day to be held in June
Faron announces R&D Day to be held in June.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n RNS Number : 1330O\n Faron Pharmaceuticals Oy\n 28 May 2020\n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n (\"Faron\" or the \"Company\")\n \n \n \n \n \n Faron announces R&D Day to be held in June\n \n \n \n \n \n \n Company announcement, 28 May 2020 at 9.00 AM (EET)\n \n \n \n \n \n \n \n \n \n \n TURKU - FINLAND \n \n - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to host a virtual R&D Day via webcast on Tuesday, 16 June 2020 at 3pm EEST, 1pm BST, 8am EDT. \n \n \n \n \n \n The event will provide an opportunity for the Company's management team to present its R&D strategy and provide insight into Faron's two clinical stage programmes. Management will discuss the Company's wholly-owned novel precision cancer immunotherapy, Clevegen, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing \n phase I/II MATINS clinical trial. Management will also discuss \n Traumakine, for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), which is currently being investigated \n in COVID-19 patients in the ongoing REMAP-CAP trial and the WHO's Solidarity trial. There will be an opportunity to ask questions during the webcast. \n \n \n \n \n \n For further information on the R&D Day, or to register for the event, please contact Consilium Strategic Communications at \n \n \n [email protected]\n \n \n \n or telephone +44 (0)20 3709 5700.\n \n \n \n \n \n \n \n \n For more information please contact:\n \n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n Dr Markku Jalkanen, Chief Executive Officer\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited, Nomad and Broker\n \n \n Emma Earl, Freddy Crossley (Corporate Finance)\n \n \n James Stearns (Corporate Broking)\n \n \n Phone: +44 207 886 2500\n \n \n \n \n \n Sisu Partners Oy, Certified Adviser on Nasdaq First North\n \n \n Juha Karttunen, Jussi Majamaa\n \n \n Phone: +358 (0)40 555 4727\n \n \n \n \n \n Consilium Strategic Communications\n \n \n Mary-Jane Elliott, David Daley, Lindsey Neville\n \n \n Phone: +44 (0)20 3709 5700\n \n \n E-mail: \...